Drug intelligence / Profile preview

Tocovid SupraBio + pentoxifylline

Development stage: Unknown
Lead developer: Hovid
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of Tocovid SupraBio (a bioenhanced full spectrum palm tocotrienol complex) and pentoxifylline. This combination was investigated for treating long-term gastrointestinal adverse effects following pelvic radiotherapy for cancer. Preclinical data suggested that combined gamma-tocotrienol with pentoxifylline could ameliorate radiotherapy-induced gastrointestinal damage. The treatment regimen consisted of Tocovid SupraBio 200 mg and pentoxifylline 400 mg, both taken orally twice daily.

Targets

PDE (Phosphodiesterase family)ADORA2B (Adenosine A2B receptor)

Beyond the preview

Go deeper on Tocovid SupraBio + pentoxifylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tocovid SupraBio + pentoxifylline.

Explore the full profile